Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells

Cancer Cell. 2015 Sep 14;28(3):281-3. doi: 10.1016/j.ccell.2015.08.009.

Abstract

NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.

Publication types

  • Review

MeSH terms

  • Bone Marrow / immunology
  • Cell Engineering / methods
  • Humans
  • Multiple Myeloma / immunology*
  • Receptors, Antigen, T-Cell / immunology*
  • T-Lymphocytes / immunology*

Substances

  • Receptors, Antigen, T-Cell